Loading
Obesity / Overweight / Chronic Weight Management · Phase 3 Trial
ClinicalTrials.gov · September 11, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a registered but actively recruiting Phase 3 randomized controlled trial of aleniglipron versus placebo in adults with obesity or overweight and type 2 diabetes. No efficacy or safety results are yet available in this registry record; the trial is designed to assess percent change in body weight over 76 weeks of treatment.
Phase 3, Interventional, Randomized, Parallel, Triple masking, Treatment purpose. Obesity, Overweight, Chronic Weight Management, Type2 Diabetes Mellitus; age from 18 Years; to 79 Years; accepts healthy volunteers. Intervention: aleniglipron Arm 1; aleniglipron Arm 2; aleniglipron Arm 3. Compared with: Placebo Arm 4 — Placebo Comparator. n = 1,100. 74 sites: United States.
This is a registered but actively recruiting Phase 3 randomized controlled trial of aleniglipron versus placebo in adults with obesity or overweight and type 2 diabetes. No efficacy or safety results are yet available in this registry record; the trial is designed to assess percent change in body weight over 76 weeks of treatment.
This is a registry record only; no results, efficacy data, or safety data are reported
The source did not state who this applies to in practice.
This is an ongoing Phase 3 trial with no results reported; the registry record describes only planned enrollment, design, and primary outcome measures.
As stated by the source record.
Quoted from the source exactly as published.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT07654374). This is a study registration, not published results. Lead sponsor: Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics. Recruitment status: RECRUITING. Phase: PHASE3. Study type: INTERVENTIONAL. Enrollment: 1100 participants (ESTIMATED). Conditions: Obesity, Overweight, Chronic Weight Management, Type2 Diabetes Mellitus. Interventions: DRUG: aleniglipron; DRUG: aleniglipron; DRUG: aleniglipron; DRUG: Placebo. Primary outcome measures: Percent change in body weight from Baseline , Baseline and week 76. Brief summary: This is randomized, double-blind, placebo-controlled study of the long-term efficacy, safety, and tolerability of multiple doses of aleniglipron in participants living with overweight or obesity and T2DM. Participants will be randomized to aleniglipron or placebo for a total of 76 weeks of treatment.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.